Decrease of serum endothelin levels with postmenopausal hormone replacement therapy or tibolone.

@article{Hnggi1999DecreaseOS,
  title={Decrease of serum endothelin levels with postmenopausal hormone replacement therapy or tibolone.},
  author={Willy H{\"a}nggi and Nick A. Bersinger and Michael M{\"u}ller and Martin H. Birkhaeuser},
  journal={Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology},
  year={1999},
  volume={13 3},
  pages={202-5}
}
Endothelin is the most potent vasoconstrictor peptide known to date. Hormone replacement therapy (HRT) with estrogen reduces plasma endothelin levels. We measured endothelin in 51 postmenopausal patients before and during HRT. Patients were randomly allocated to receive either oral tibolone, oral or transdermal 17 beta-estradiol. A group of comparable volunteers served as controls. After 24 months, endothelin levels decreased in all treatment groups: tibolone, 18.2%; oral 23.1%; transdermal, 20… CONTINUE READING